Clinical Trials

MainTitle

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

This study has been completed
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator
Hoffmann-La Roche

Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier
NCT00001034

First received: November 2, 1999
Last updated: September 28, 2013
Last Verified: September 2013
History of Changes
Purpose

Purpose

To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected patients with severe immunosuppression.

The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until recently, both drugs required intravenous administration. An oral form of ganciclovir, if shown to be effective therapy against CMV, would be a more suitable method of administration for prophylaxis.

Condition Intervention Phase
Cytomegalovirus Retinitis
HIV Infections
Gastrointestinal Diseases

Drug : Ganciclovir
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Enrollment: 850
Study Completion Date: August 1995

Detailed Description:

The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until recently, both drugs required intravenous administration. An oral form of ganciclovir, if shown to be effective therapy against CMV, would be a more suitable method of administration for prophylaxis.
Patients are randomized in a 2:1 ratio to receive either oral ganciclovir or placebo for a minimum of 12 months. PER AMENDMENT 9/19/94: Patients who have not reached a study endpoint may choose to continue blinded prophylaxis or discontinue blinded prophylaxis and begin open-label ganciclovir. PER AMENDMENT 5/2/95: After the common closing date (6/3/95) patients who have not met a CMV end point or experienced a serious toxicity that required permanent discontinuation of active oral ganciclovir will be eligible to receive open-label oral ganciclovir through an open-label extension phase of study 023 until 8/31/95.

Eligibility

Eligibility

Ages Eligible for Study: 13 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria
Concurrent Medication:
Allowed:

  • Antiretroviral therapy.
  • Anti-PCP prophylaxis.
  • Maintenance or prophylaxis therapy for other opportunistic infections besides CMV.

  • Patients must have:
  • Working diagnosis of HIV infection.
  • CD4 count <= 100 cells/mm3.
  • Positive CMV serology (IgG) or CMV culture, in the absence of active disease, documented at any time prior to study entry.
  • Reasonably good health.
  • Life expectancy of at least 6 months.

  • Exclusion Criteria
    Co-existing Condition:
    Patients with the following symptoms or conditions are excluded:
  • Acute life-threatening illness.
  • Active lymphoma.
  • Hypersensitivity to acyclovir.
  • Lack of willingness or ability, in the opinion of the clinician, to comply with protocol requirements.

  • Concurrent Medication:
    Excluded:
  • Vidarabine.
  • Amantadine hydrochloride (Symmetrel).
  • CMV hyperimmune globulin/intravenous immune globulin.
  • Cytarabine.
  • Fiacitabine (FIAC) or fialuridine (FIAU).
  • Foscarnet.
  • Intravenous ganciclovir.
  • HPMPC.
  • Idoxuridine.
  • Intravenous acyclovir.
  • Oral acyclovir at > 1 g/day.
  • Other drugs with potential anti-CMV activity.

  • Prior Medication:
    Excluded within 60 days prior to study entry:
  • Foscarnet.

  • Excluded within 2 weeks prior to study entry:
  • Vidarabine.
  • Amantadine hydrochloride (Symmetrel).
  • CMV hyperimmune globulin/intravenous immune globulin.
  • Cytarabine.
  • Fiacitabine (FIAC) or fialuridine (FIAU).
  • Ganciclovir.
  • HPMPC.
  • Idoxuridine.
  • Intravenous acyclovir.
  • Oral acyclovir at > 1 g/day.
  • Other drugs with potential anti-CMV activity.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001034

Locations

United States, California
Community Consortium of San Francisco
San Francisco, California, United States, 94110
United States, Colorado
Denver CPCRA / Denver Public Hlth
Denver, Colorado, United States, 80204
United States, Delaware
Wilmington Hosp / Med Ctr of Delaware
Wilmington, Delaware, United States, 19899
United States, District of Columbia
Veterans Administration Med Ctr / Regional AIDS Program
Washington, District of Columbia, United States, 20422
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30308
United States, Illinois
AIDS Research Alliance - Chicago
Chicago, Illinois, United States, 60657
United States, Louisiana
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana, United States, 70112
United States, Michigan
Comprehensive AIDS Alliance of Detroit
Detroit, Michigan, United States, 48201
Henry Ford Hosp
Detroit, Michigan, United States, 48202
United States, New Jersey
Schering - Plough Corp
Kenilworth, New Jersey, United States, 07033
North Jersey Community Research Initiative
Newark, New Jersey, United States, 07103
United States, New York
Bronx Lebanon Hosp Ctr
Bronx, New York, United States, 10456
Addiction Research and Treatment Corp
Brooklyn, New York, United States, 11201
Clinical Directors Network of Region II
New York, New York, United States, 10011
Harlem AIDS Treatment Group / Harlem Hosp Ctr
New York, New York, United States, 10037
United States, Oregon
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, United States, 97210
United States, Virginia
Richmond AIDS Consortium
Richmond, Virginia, United States, 23298

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
Hoffmann-La Roche

Investigators

Study Chair: Brosgart C
Study Chair: Craig C
More Information

More Information


Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT00001034   History of Changes  
Other Study ID Numbers: CPCRA 023  
  11573  
Study First Received: November 2, 1999  
Last Updated: September 28, 2013  

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Retinitis
Ganciclovir
Cytomegalovirus Infections
Administration, Oral
Acquired Immunodeficiency Syndrome
Gastrointestinal System

Additional relevant MeSH terms:
HIV Infections
Retinitis
Gastrointestinal Diseases
Digestive System Diseases
Cytomegalovirus Retinitis
Ganciclovir
Ganciclovir triphosphate

ClinicalTrials.gov processed this data on December 08, 2017
This information is provided by ClinicalTrials.gov.